賽諾醫療(688108.SH):公司神經介入板塊建立了覆蓋全國的神經介入銷售渠道
格隆匯6月12日丨有投資者向賽諾醫療(688108.SH)提問:神經介入通路類產品陸續上市,競爭激烈,公司進院及銷售的抓手是什麼?
賽諾醫療回覆:公司自成立以來,主營產品冠脈藥物支架、冠脈球囊、顱內快速交換球囊、顱內藥物洗脱支架等產品已進入千餘家醫院,這是一個基礎;其次我們在進行神經產品線的配置時,充分考慮了產品未來的競爭力,重點考慮產品的稀缺性,以及產品差異化等因素;除此之外,公司神經介入板塊建立了覆蓋全國的神經介入銷售渠道,在售的神經介入產品進入多家臨牀中心。公司將充分利用現有的資源、進一步優化營銷團隊、拓展銷售途徑,從而不斷的擴大產品覆蓋醫院數量、擴寬產品的銷售渠道。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.